Browse the evidence

GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide) reduce major adverse cardiovascular events (MACE) in obese patients without diabetes, independent of weight loss alone.

If you are obese and have existing heart disease, ask your doctor about GLP-1 agonists like semaglutide. They significantly lower your risk of heart attack and stroke, offering protection beyond just weight loss.

GLP-1 and GIP/GLP-1 agonists improve heart failure with preserved ejection fraction (HFpEF) symptoms and functional capacity in obese patients, independent of diabetes status.

If you have obesity and heart failure with preserved ejection fraction, discuss GLP-1 agonists with your cardiologist. They can significantly improve your heart failure symptoms, exercise capacity, and quality of life.

GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.

For patients with type 2 diabetes and existing heart disease, GLP-1 therapies like liraglutide and semaglutide significantly reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death). This benefit exists alongside weight loss and may be partly due to direct protective effects on the heart and blood vessels. These drugs are now a standard part of care for high-risk diabetic patients.

Osteosarcopenia is defined by the simultaneous loss of muscle mass, muscle strength, bone mass, and functional capacity, and is associated with significantly higher risks of falls, fractures, and mortality compared to having either condition alone.

Osteosarcopenia is the dangerous combination of weak muscles and weak bones. It significantly increases your risk of falls, fractures, and death compared to having just one of these conditions. A comprehensive assessment should check both muscle and bone health.

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death, heart failure hospitalizations, and renal composite outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of baseline glycemic control.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These medications are proven to significantly lower your risk of heart failure, kidney failure, and death, offering protection beyond just blood sugar control.

GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.

For those with Type 2 Diabetes and high heart risk, GLP-1 agonists like liraglutide or semaglutide offer strong protection against heart attacks and strokes, as well as kidney damage. Discuss these options with your doctor, especially if you are overweight.

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about SGLT-2 inhibitors (like empagliflozin or dapagliflozin). These drugs protect your heart and kidneys beyond just lowering blood sugar, significantly reducing the risk of heart failure hospitalization and death. Be aware of potential side effects like infections, but discuss how the heart benefits may outweigh these risks for your specific health profile.

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with Type 2 Diabetes and established CVD, primarily through weight loss, blood pressure reduction, and anti-inflammatory effects.

If you have Type 2 Diabetes and heart disease, GLP-1 agonists (like semaglutide or liraglutide) are highly effective at reducing the risk of heart attacks, strokes, and death. They work by mimicking a gut hormone to lower blood sugar, promote weight loss, and reduce blood pressure. While they require injections and may cause temporary stomach issues, the heart protection benefits are substantial and well-documented.

Obesity increases the risk of various cancers (e.g., breast, colorectal, liver) through mechanisms involving chronic inflammation, oxidative stress, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin).

Obesity increases your risk for several types of cancer through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity contributes to cardiovascular disease (CVD) through mechanisms including adipose tissue dysfunction, ectopic fat deposition, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin), leading to hypertension, atherosclerosis, and heart failure.

Obesity increases your risk for heart disease and stroke through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity is a primary driver of Heart Failure with Preserved Ejection Fraction (HFpEF) through cardiometabolic mechanisms including systemic inflammation, lipotoxicity, and metabolic remodeling, rather than being merely a comorbidity.

If you have HFpEF and obesity, your body's metabolism and inflammation are likely driving your heart condition. This is not just about 'being overweight' but involves complex biological changes like fat toxicity and inflammation. Managing obesity through weight loss interventions (like GLP-1 agonists or lifestyle changes) can target these root causes and improve heart health.

Discontinuation of semaglutide or tirzepatide leads to significant weight regain, indicating that these therapies require long-term use to maintain metabolic benefits.

If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost. These drugs treat obesity and diabetes as chronic conditions, meaning they are meant to be taken long-term to maintain the health benefits. Stopping them reverses the progress made.

A 12-month healthy low-carbohydrate diet and a healthy low-fat diet produce statistically equivalent weight loss in overweight adults, with no significant difference between the two approaches.

For overweight adults, both a healthy low-fat diet and a healthy low-carbohydrate diet lead to similar weight loss over 12 months. The specific macronutrient ratio matters less than the quality of food (whole foods, minimal processing) and the ability to adhere to the diet long-term. You do not need genetic testing or insulin measurements to choose between them; pick the one you can sustain.

Rapid weight loss via a low-energy diet (810 kcal/day for 8 weeks) induces gender-specific metabolic adaptations: men lose more total body weight and fat mass with greater improvements in metabolic syndrome Z-score, whereas women lose relatively more fat-free mass and experience larger reductions in HDL cholesterol and hip circumference, despite similar improvements in insulin resistance.

If you are using a very low-calorie diet (around 800 kcal/day) to jumpstart weight loss, expect different results based on your sex. Men will likely lose more total weight and fat, with better improvements in overall metabolic risk. Women may lose less total weight but will still improve insulin resistance. However, women should be aware that this specific rapid loss phase may lead to greater loss of lean muscle and a drop in 'good' cholesterol (HDL). This doesn't mean the diet is 'bad' for women, but it highlights the need for careful monitoring and a strong focus on preserving muscle mass (via protein and resistance training) once you transition to a maintenance diet.

Low carbohydrate diets are not significantly superior to low fat diets for weight loss when protein content is held constant.

You do not need to choose between low-carb and low-fat based on efficacy; both work equally well if you stick to them. Focus on adherence and protein intake rather than eliminating entire food groups, as no single diet is superior.

Men experience greater magnitude of weight loss and cardiometabolic improvement (insulin sensitivity, lipids) from low-calorie diets than women, but women maintain these benefits better during weight maintenance due to lower metabolic rebound.

If you are a woman, expect your initial weight loss on a strict low-calorie diet to be slower than a man's, but recognize that your body may be better at keeping your blood fats and insulin sensitivity stable once you stop dieting. Focus on the long-term maintenance of health markers rather than just the scale number during the first 8 weeks.

Intermittent fasting (IMF) and daily caloric restriction (DCR) produce equivalent weight loss when matched for energy deficit and delivered with guideline-based behavioral support and physical activity prescriptions.

To lose weight effectively, you can choose either daily calorie restriction or intermittent fasting, but the key is consistency and support. Ensure your total weekly energy deficit is similar regardless of the method. Crucially, engage in a structured behavioral support program that includes regular check-ins, goal setting, and physical activity (aiming for 300 minutes of moderate exercise per week). This structured approach is more important than the specific timing of your meals for long-term success.

Ad libitum low-carbohydrate diets promote weight loss without significant fat mass reduction, whereas ad libitum low-fat diets promote significant fat mass loss, indicating that early weight loss on low-carb diets does not necessarily reflect negative energy balance or fat loss.

If your goal is fat loss, a low-fat diet may be more effective than a low-carb diet when eating ad libitum, as low-carb diets may result in weight loss driven by water and glycogen depletion rather than fat loss. Focus on body composition changes (like DEXA scans or progress photos) rather than just scale weight when starting a low-carb diet.

There is no significant difference in the reduction of absolute fat mass (kg) or waist circumference between low-carbohydrate and low-fat diets.

While LCDs may lower BMI and body fat percentage more than LFDs, they do not necessarily reduce absolute fat mass (kg) or waist circumference more effectively. If waist circumference is your primary goal, either diet may be equally effective.

Semaglutide treatment is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) compared to placebo, though these are mostly mild to moderate.

Be prepared for gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but usually mild and temporary. Titration helps manage them.

High body mass index (BMI) is a causal risk factor for a broad spectrum of chronic diseases, including cardiovascular disease, diabetes, chronic kidney disease, multiple cancers, and musculoskeletal disorders, resulting in significant global mortality and disease burden.

Maintaining a BMI within the 20-25 kg/m2 range is associated with the lowest all-cause mortality risk. This is not just about weight but about reducing the risk of major chronic diseases like heart disease, diabetes, and certain cancers. Public health surveillance and evidence-based interventions are critical to addressing this growing burden.

A significant portion of deaths related to high BMI occur among individuals who are not clinically obese (BMI < 30 kg/m2), indicating that overweight status (BMI 25-29.9) also carries substantial mortality risk.

You do not need to be obese to face increased health risks. Being overweight (BMI 25-29.9) accounts for a large portion of deaths related to high body weight. Aim for a BMI in the 20-25 range to minimize mortality risk.

Cardiovascular disease is the primary cause of death associated with high BMI, accounting for more than two-thirds of high-BMI-related deaths.

Heart disease is the biggest killer linked to high body weight. Keeping your BMI in the 20-25 range is one of the most effective ways to protect your heart.

High body-mass index (BMI) is a significant metabolic risk factor with increasing exposure rates (1.8% annually) and a 15.7% rise in age-standardized DALY rates from 2000 to 2021.

High BMI is a significant metabolic risk factor with increasing exposure rates. Addressing high BMI is crucial for long-term health.